Available biochemical and clinical data are sufficiently compelling to recommend low dose or transdermal hormone therapy for the management of menopausal symptoms when possible. Women initiating low dose or transdermal hormone therapy are not at increased risk of cardiovascular disease, stroke, venous thrombotic disease, and breast cancer. Evidence suggests that these outcomes are favorably affected by low-dose hormone therapy and persist with continuation of therapy.
|Number of pages||11|
|Journal||Clinical Obstetrics and Gynecology|
|State||Published - Sep 2008|
- Hormone therapy